US 12,233,137 B1
PSMA targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy
Martin G. Pomper, Baltimore, MD (US); Ronnie C. Mease, Fairfax, VA (US); Vivek Kumar, Rensselaer, NY (US); Sangeeta Ray, Ellicott City, MD (US); Michael Zalutsky, Chapel Hill, NC (US); and Ganesan Vaidyanathan, Chapel Hill, NC (US)
Assigned to The Johns Hopkins University, Baltimore, MD (US); and Duke University, Durham, NC (US)
Filed by The Johns Hopkins University, Baltimore, MD (US); and Duke University, Durham, NC (US)
Filed on Aug. 11, 2023, as Appl. No. 18/448,682.
Application 18/448,682 is a continuation of application No. 16/967,488, granted, now 11,813,340, previously published as PCT/US2019/016821, filed on Feb. 6, 2019.
Claims priority of provisional application 62/626,993, filed on Feb. 6, 2018.
Int. Cl. A61K 51/04 (2006.01); A61K 47/18 (2017.01); A61P 35/00 (2006.01); C07B 39/00 (2006.01); C07B 59/00 (2006.01)
CPC A61K 51/0482 (2013.01) [A61K 47/18 (2013.01); A61P 35/00 (2018.01); C07B 39/00 (2013.01); C07B 59/004 (2013.01); A61K 2121/00 (2013.01); C12Y 304/17021 (2013.01)] 20 Claims
 
1. A compound of the following formula:

OG Complex Work Unit Chemistry
wherein:
p is an integer selected from the group consisting of 1, 2, 3, 4, 5, and 6; and
X is halogen;
X1 is —CR3 or N, wherein R3 is H or C1-C4 alkyl; and
X2 is selected from the group consisting of a radioisotope of iodine, a radioisotope of bromine, and a radioisotope of astatine; and
wherein M+ is a metal, which can be present or absent.